Ironsides Asset Advisors, LLC Kezar Life Sciences, Inc. Transaction History

Ironsides Asset Advisors, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 04, 2022	BUY	$7.99 - $10.75 $2,397 - $3,225	300 Added 2.82%	10,920 $94,000
Q2 2022 Aug 09, 2022	SELL	$4.58 - $17.13 $1,832 - $6,852	-400 Reduced 3.63%	10,620 $88,000
Q4 2021 Feb 04, 2022	SELL	$7.44 - $16.72 $372 - $836	-50 Reduced 0.45%	11,020 $184,000
Q3 2021 Nov 16, 2021	SELL	$4.85 - $9.73 $27,838 - $55,850	-5,740 Reduced 34.15%	11,070 $96,000
Q2 2021 Aug 06, 2021	SELL	$4.93 - $6.46 $18,832 - $24,677	-3,820 Reduced 18.52%	16,810 $91,000
Q1 2021 May 07, 2021	BUY	$5.24 - $6.99 $1,572 - $2,097	300 Added 1.48%	20,630 $123,000
Q4 2020 Feb 10, 2021	BUY	$4.77 - $6.58 $7,274 - $10,034	1,525 Added 8.11%	20,330 $106,000
Q3 2020 Nov 10, 2020	BUY	$4.36 - $5.5 $12,229 - $15,427	2,805 Added 17.53%	18,805 $91,000
Q1 2020 May 11, 2020	BUY	$2.77 - $5.75 $44,320 - $92,000	16,000 New	16,000 $70,000
Q4 2019 Jan 21, 2020	SELL	$2.5 - $4.26 $44,125 - $75,189	-17,650 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$7.09 - $21.9 $41,731 - $128,903	5,886 Added 50.03%	17,650 $136,000
Q1 2019 May 08, 2019	BUY	$16.83 - $23.75 $197,988 - $279,395	11,764 New	11,764 $209,000

38.2M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $433M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Ironsides Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Ironsides Asset Advisors, LLC with notifications on news.